121 related articles for article (PubMed ID: 33170223)
1. Investigational KRAS Inhibitor Tested for Advanced Solid Tumors.
Abbasi J
JAMA; 2020 Nov; 324(18):1818. PubMed ID: 33170223
[No Abstract] [Full Text] [Related]
2. Dueling KRAS
Cancer Discov; 2020 Jan; 10(1):10. PubMed ID: 31822538
[TBL] [Abstract][Full Text] [Related]
3. KRAS inhibitors, approved.
Rosell R; Aguilar A; Pedraz C; Chaib I
Nat Cancer; 2021 Dec; 2(12):1254-1256. PubMed ID: 35121930
[No Abstract] [Full Text] [Related]
4. IASLC 2019 World Conference on Lung Cancer.
Venkatesan P
Lancet Respir Med; 2019 Nov; 7(11):930-932. PubMed ID: 31548107
[No Abstract] [Full Text] [Related]
5. Targeting the KRAS G12C mutation in patients with advanced solid tumors.
Hong DS
Clin Adv Hematol Oncol; 2019 Nov; 17(11):612-614. PubMed ID: 31851163
[No Abstract] [Full Text] [Related]
6. Mechanisms of Resistance to KRAS
Akhave NS; Biter AB; Hong DS
Cancer Discov; 2021 Jun; 11(6):1345-1352. PubMed ID: 33820777
[No Abstract] [Full Text] [Related]
7. Targeted therapy for non-small cell lung cancer.
Toloza EM; D'Amico TA
Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
[TBL] [Abstract][Full Text] [Related]
8. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
[TBL] [Abstract][Full Text] [Related]
9. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
10. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS
J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Shepherd FA
J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
[No Abstract] [Full Text] [Related]
14. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
15. KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.
Renaud S; Guerrera F; Seitlinger J; Reeb J; Voegeli AC; Legrain M; Mennecier B; Santelmo N; Falcoz PE; Quoix E; Chenard MP; Weingertner N; Beau-Faller M; Massard G
Clin Lung Cancer; 2018 Nov; 19(6):e919-e931. PubMed ID: 30217639
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M; Ganzinelli M; Garassino MC; Shepherd FA; Piva S; Caiola E; Macerelli M; Bettini A; Lauricella C; Floriani I; Farina G; Longo F; Bonomi L; Fabbri MA; Veronese S; Marsoni S; Broggini M; Rulli E
Oncotarget; 2015 Oct; 6(32):34014-22. PubMed ID: 26416458
[TBL] [Abstract][Full Text] [Related]
19. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
20. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Cottini F; Lautenschlaeger T
Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
